论文部分内容阅读
目的 观察乙型肝炎病毒(HBV)转基因鼠孕期使用拉米夫定和干扰素,对降低HBV水平的作用及其对母胎安全性的影响。方法 将高滴度表达HBsAg的HBV转基因鼠35只分成5个研究组,每组7只。研究组1和研究组2分别从孕第5天(孕早期)和孕第10天(孕中期)开始给予拉米夫定100mg/(kg·d)直至分娩;研究组3和研究组4从孕第5天和孕第10天分别给予干扰素5MU/(m2·2d);研究组5给予生理盐水。检测各研究组实验鼠用药前、后血中HBsAg、HBVDNA等水平的变化。另选18只普通孕鼠(清洁级)分为对照组1、对照组2及对照组3(每组6只),分别给予拉米夫定、干扰素和生理盐水(剂量与研究组相同)。观察各研究组及各对照组实验鼠、胎鼠及新生鼠的安全性相关指标。结果 (1)HBsAg滴度变化:研究组1实验鼠,用药后平均血清HBsAg滴度由用药前的(166±98)ng/ml降至用药后的(82±59)ng/ml,用药前后血清HBsAg滴度比较,差异有统计学意义(P<0 .05);研究组2实验鼠,用药后平均血清HBsAg滴度虽由用药前的( 159±49 )ng/ml也降至用药后的(82±60)ng/ml,但用药前后血清HBsAg滴度比较,差异均无统计学意义(P>0 .05);其余各组实验鼠用药前后血清HBsAg滴度比较,差异均无统计学意义(P>0 .05)。(2)HBVDNA滴度变化:研究组1和研究组2的HBVDNA阳性鼠,HBVDNA滴度由用药
Objective To observe the effect of lamivudine and interferon on the reduction of HBV in pregnant women with hepatitis B virus (HBV) during pregnancy and its effect on the safety of mother’s fetus. Methods 35 high-titer HBV transgenic mice expressing HBsAg were divided into 5 groups, 7 in each group. Study group 1 and study group 2 received lamivudine 100 mg / (kg · d) from the fifth day of gestation (first trimester) and the tenth day of gestation (second trimester) until delivery; study group 3 and study group 4 Interferon 5MU / (m2 · 2d) was given on the 5th day of pregnancy and the 10th day of pregnancy respectively. The study group 5 was given normal saline. The levels of HBsAg and HBVDNA in blood of each study group were measured before and after treatment. Another 18 normal pregnant rats (clean grade) were divided into control group 1, control group 2 and control group 3 (6 in each group), and were given lamivudine, interferon and saline respectively (the same dosage as the study group) . Observe the safety-related indexes of experimental mice, fetuses and neonates in each study group and each control group. Results (1) HBsAg titer change: The average serum HBsAg titer decreased from (166 ± 98) ng / ml in the study group 1 to (82 ± 59) ng / ml before and after treatment, Serum HBsAg titers were significantly different (P <0. 05). The mean serum HBsAg titer in study group 2 experimental mice decreased from (159 ± 49) ng / ml before treatment to (82 ± 60) ng / ml, but there was no significant difference in the serum HBsAg titers before and after treatment (P> 0.05). There was no statistical difference in serum HBsAg titers between the other groups before and after treatment Significance of learning (P> 0.05). (2) HBVDNA titer change: HBVDNA positive mice in study group 1 and study group 2, HBVDNA titer by the medication